Skip to main content

H Lundbeck

H. Lundbeck is a global specialty pharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for brain diseases. The firm focuses its research and development efforts primarily on psychiatric and neurological disorders, including major depressive disorder, schizophrenia, Parkinson's disease, and Alzheimer's disease. Its product portfolio features established pharmaceutical brands prescribed by medical professionals to treat complex central nervous system conditions worldwide. Principal revenue drivers stem from global commercial sales of prescription medicines to healthcare providers, hospitals, and distribution partners. The company maintains a significant international scale and a specialized market position within neuroscience pharmaceuticals, serving patients across numerous countries. Lundbeck is officially headquartered in Valby, Denmark, and its shares are publicly listed and traded on the Nasdaq Copenhagen exchange.

42 of the funds FundTelligence covers report a position in H Lundbeck.

Legal name
H Lundbeck A/S
Sector
Health Care
Country
Denmark
Funds holding it
42
Exposure themes
Depression & Mood Disorders, Mental Health, Psychiatry

Funds holding H Lundbeck

Showing the 8 largest of 42 funds holding it.

Loading...